- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00186251
High Dose Chemotherapy Followed By PBSC Rescue for HD
November 9, 2012 updated by: Stanford University
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease
To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease
Study Type
Interventional
Enrollment
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 weeks to 70 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:- adequate organ function
- recurrent HD Exclusion Criteria:- CNS disease
- no prior malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Overall survival
|
Response rates
|
FFS
|
Secondary Outcome Measures
Outcome Measure |
---|
Toxicity of high dose chemotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sally Arai, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 1998
Study Completion
July 1, 2005
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 16, 2005
Study Record Updates
Last Update Posted (Estimate)
November 12, 2012
Last Update Submitted That Met QC Criteria
November 9, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BMT24
- 13322 (Other Identifier: Stanford IRB)
- NCT00186251
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin Disease
-
Tessa TherapeuticsActive, not recruitingHodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, PediatricUnited States
-
Tessa TherapeuticsBristol-Myers SquibbActive, not recruitingClassical Hodgkin Lymphoma | Hodgkin Disease Recurrent | Hodgkin Disease RefractoryUnited States
-
Shandong Provincial HospitalUnknownLymphoma, Non-Hodgkin;Hodgkin DiseaseChina
-
AkesoPeking University Cancer Hospital & InstituteRecruiting
-
Stanford UniversityCompletedLymphoma | Hodgkin Disease | Lymphoma, Hodgkin Disease | Lymphoma: HodgkinUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Grupo Argentino de Tratamiento de la Leucemia AgudaTakedaRecruitingRefractory Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Relapsed Hodgkin's Disease, AdultArgentina
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, France, Canada, Belgium, Italy
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, Canada
Clinical Trials on high dose chemo then auto hematopoietic cell transplant
-
Stanford UniversityCompletedAmyloidosis | Blood and Marrow Transplant (BMT)United States
-
Stanford UniversityNational Institutes of Health (NIH)Completed
-
Stanford UniversityUnknownGraft vs Host DiseaseUnited States
-
Stanford UniversityCompletedBreast CancerUnited States
-
Stanford UniversityCompletedLeukemia, Lymphocytic, ChronicUnited States
-
Stanford UniversityCompletedLeukemia | Leukemia, Myelocytic, Acute | Blood and Marrow Transplant (BMT)United States
-
Stanford UniversityCompletedMultiple MyelomaUnited States
-
Stanford UniversityCompletedGraft vs Host Disease | Blood and Marrow Transplant (BMT)United States
-
David Rizzieri, MDCompletedSickle Cell Anemia | Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Severe Aplastic AnemiaUnited States
-
Massachusetts General HospitalDana-Farber Cancer Institute; Genentech, Inc.; Otsuka America PharmaceuticalCompletedNon-Hodgkin's Lymphoma | CNS LymphomaUnited States